This document provides an investor presentation for Valeritas Holdings, Inc. discussing their V-Go disposable insulin delivery device. It highlights the large market opportunity in the Type 2 diabetes market, the clinical benefits shown to improve A1C and quality of life, and the established reimbursement and commercial infrastructure. The presentation provides an overview of the company's commercialization progress and strategy to expand adoption and sales of V-Go as a simple, discreet, cost-effective basal-bolus insulin delivery option.
Valeritas is presenting their V-Go insulin delivery device to investors. The device addresses unmet needs for the 4.6 million type 2 diabetes patients in the US who require basal and bolus insulin but are not achieving optimal blood sugar control. Extensive clinical studies show that switching to V-Go significantly reduces A1C levels and total daily insulin dose compared to multiple daily injections, improving health outcomes and quality of life. Valeritas has commercialized V-Go in the US and aims to capitalize on the large $15 billion market opportunity for these patients through a focused commercial strategy and efficient manufacturing model.
1) The document provides confidential information about Valeritas, Inc. to shareholders, including an overview of their V-Go insulin delivery device, clinical data demonstrating its effectiveness at lowering A1C levels and daily insulin doses, and the experience and focus of the leadership team.
2) Valeritas believes V-Go is well-positioned for success due to its ability to address unmet needs in the large type 2 diabetes market, its demonstrated commercial traction, established reimbursement, and capital efficient strategy.
3) Clinical studies show patients experienced statistically significant improvements in A1C levels and reductions in daily insulin needs after switching to V-Go from multiple daily injections.
Art 920 rev-d-valeritas investor presentation_final_04.03.17valeritasir
Valeritas is an investor presentation for NASDAQ: VLRX discussing their V-Go wearable insulin delivery device. In 3 sentences:
Valeritas provides a simple, discreet and easy-to-use insulin delivery device called V-Go that has strong clinical data showing reductions in A1C levels. V-Go has established reimbursement and is a cost-effective option for both patients and payors. The presentation outlines Valeritas' commercial strategy and financial profile, demonstrating potential for revenue growth while reducing operating expenses and cash burn.
AIS Investor presentation.pw. february 2011rymankoly
This document summarizes Antares Pharma's business and product pipeline. It highlights the company's growing revenues, deep product pipeline including late stage programs like Anturol for overactive bladder and partnerships with Teva and BioSante. Antares has a strong cash position of over $10 million and is reducing its cash burn rate while advancing multiple proprietary and partnered programs toward commercialization and significant news flow.
Art 923 rev-c-updating investor presentation on valeritas website_final_12.05.16valeritasir
V-Go is a single-use, fully disposable insulin delivery device that provides basal and bolus insulin. It addresses the needs of the 4.6 million Type 2 diabetes patients in the US who require insulin but are not achieving treatment goals. Extensive clinical data shows V-Go lowers A1C levels and total daily insulin dose. It has established reimbursement through pharmacy benefits, making it cost-neutral for payors and patients compared to insulin pens. Valeritas sees significant growth opportunities by expanding its sales force to reach more prescribers.
Valeritas provides a corporate presentation on their V-Go insulin delivery device. Key points include:
- V-Go is a single-use, fully disposable insulin delivery device worn like a patch that provides 24-hour basal and bolus insulin delivery with no programming.
- It is designed to simplify insulin delivery for patients with type 2 diabetes compared to multiple daily injections, improving adherence and health outcomes.
- With over 4.5 million patients in the US with type 2 diabetes taking insulin but not at glucose goals, V-Go represents a significant market opportunity of over $1 billion if it captures 15% market share.
- Clinical studies show V-Go lowers A1C, improves quality of
Art 920 rev-g-valeritas-investor-presentation_final_11.03.17valeritasir
V-Go is a wearable insulin delivery device that addresses unmet needs for the 4.5 million patients in the US with type 2 diabetes on insulin who are not achieving their A1C goals. It provides both basal and bolus insulin delivery in a discreet, easy-to-use device to improve poor adherence commonly seen with multiple daily injections. Clinical data shows patients achieve better glycemic control and report high satisfaction with V-Go's convenience and ability to fit their lifestyle.
Art 1236 rev a-valeritas investor deck 2.0 final_031218bvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device that provides both basal and bolus insulin through a single-use, disposable patch. V-Go aims to help the millions of type 2 diabetes patients in the US who take insulin but struggle with adherence to multiple daily injections. Valeritas believes V-Go can become the preferred insulin delivery method for these patients by eliminating the need for injections. They are currently growing revenue quarter-over-quarter and targeting a $1.6 billion market opportunity by achieving a 15% share of the type 2 diabetes patients in the US who are not reaching their
Valeritas is presenting their V-Go insulin delivery device to investors. The device addresses unmet needs for the 4.6 million type 2 diabetes patients in the US who require basal and bolus insulin but are not achieving optimal blood sugar control. Extensive clinical studies show that switching to V-Go significantly reduces A1C levels and total daily insulin dose compared to multiple daily injections, improving health outcomes and quality of life. Valeritas has commercialized V-Go in the US and aims to capitalize on the large $15 billion market opportunity for these patients through a focused commercial strategy and efficient manufacturing model.
1) The document provides confidential information about Valeritas, Inc. to shareholders, including an overview of their V-Go insulin delivery device, clinical data demonstrating its effectiveness at lowering A1C levels and daily insulin doses, and the experience and focus of the leadership team.
2) Valeritas believes V-Go is well-positioned for success due to its ability to address unmet needs in the large type 2 diabetes market, its demonstrated commercial traction, established reimbursement, and capital efficient strategy.
3) Clinical studies show patients experienced statistically significant improvements in A1C levels and reductions in daily insulin needs after switching to V-Go from multiple daily injections.
Art 920 rev-d-valeritas investor presentation_final_04.03.17valeritasir
Valeritas is an investor presentation for NASDAQ: VLRX discussing their V-Go wearable insulin delivery device. In 3 sentences:
Valeritas provides a simple, discreet and easy-to-use insulin delivery device called V-Go that has strong clinical data showing reductions in A1C levels. V-Go has established reimbursement and is a cost-effective option for both patients and payors. The presentation outlines Valeritas' commercial strategy and financial profile, demonstrating potential for revenue growth while reducing operating expenses and cash burn.
AIS Investor presentation.pw. february 2011rymankoly
This document summarizes Antares Pharma's business and product pipeline. It highlights the company's growing revenues, deep product pipeline including late stage programs like Anturol for overactive bladder and partnerships with Teva and BioSante. Antares has a strong cash position of over $10 million and is reducing its cash burn rate while advancing multiple proprietary and partnered programs toward commercialization and significant news flow.
Art 923 rev-c-updating investor presentation on valeritas website_final_12.05.16valeritasir
V-Go is a single-use, fully disposable insulin delivery device that provides basal and bolus insulin. It addresses the needs of the 4.6 million Type 2 diabetes patients in the US who require insulin but are not achieving treatment goals. Extensive clinical data shows V-Go lowers A1C levels and total daily insulin dose. It has established reimbursement through pharmacy benefits, making it cost-neutral for payors and patients compared to insulin pens. Valeritas sees significant growth opportunities by expanding its sales force to reach more prescribers.
Valeritas provides a corporate presentation on their V-Go insulin delivery device. Key points include:
- V-Go is a single-use, fully disposable insulin delivery device worn like a patch that provides 24-hour basal and bolus insulin delivery with no programming.
- It is designed to simplify insulin delivery for patients with type 2 diabetes compared to multiple daily injections, improving adherence and health outcomes.
- With over 4.5 million patients in the US with type 2 diabetes taking insulin but not at glucose goals, V-Go represents a significant market opportunity of over $1 billion if it captures 15% market share.
- Clinical studies show V-Go lowers A1C, improves quality of
Art 920 rev-g-valeritas-investor-presentation_final_11.03.17valeritasir
V-Go is a wearable insulin delivery device that addresses unmet needs for the 4.5 million patients in the US with type 2 diabetes on insulin who are not achieving their A1C goals. It provides both basal and bolus insulin delivery in a discreet, easy-to-use device to improve poor adherence commonly seen with multiple daily injections. Clinical data shows patients achieve better glycemic control and report high satisfaction with V-Go's convenience and ability to fit their lifestyle.
Art 1236 rev a-valeritas investor deck 2.0 final_031218bvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device that provides both basal and bolus insulin through a single-use, disposable patch. V-Go aims to help the millions of type 2 diabetes patients in the US who take insulin but struggle with adherence to multiple daily injections. Valeritas believes V-Go can become the preferred insulin delivery method for these patients by eliminating the need for injections. They are currently growing revenue quarter-over-quarter and targeting a $1.6 billion market opportunity by achieving a 15% share of the type 2 diabetes patients in the US who are not reaching their
Art 1236 rev a-valeritas investor deck 2.0 final_031218bvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device that provides both basal and bolus insulin through a single-use, disposable patch. V-Go aims to help the millions of type 2 diabetes patients in the US who take insulin but struggle with adherence to multiple daily injections. Valeritas believes V-Go can become the preferred insulin delivery method for these patients by eliminating the need for injections. They are currently growing revenue quarter-over-quarter and targeting a $1.6 billion market opportunity by achieving a 15% share of the type 2 diabetes patients in the US who are not reaching their
Art 1236 rev c-valeritas investor deck 2.0_final_080618 web versionvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device for patients with type 2 diabetes. The presentation discusses Valeritas' significant market opportunity in the global diabetes pandemic, validates their new high-touch sales model which is driving accelerating revenue growth, and presents their attractive financial profile and path to profitability. Key risks to their projections include reliance on V-Go for revenue, ability to retain customers and achieve market acceptance, and manufacturing risks.
Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
What the Shift to Value Means for PharmaceuticalsMedullan
With the transition to value, payers are insisting that pharmaceutical manufacturers deliver real world evidence of their drug’s efficacy before being allowed on formulary. The cost of new specialty treatments has forced companies to bolster and go beyond clinical trial, proving that their drugs improve health outcomes and reduce the cost of care in actual use. Gathering and compiling the myriad of needed data points requires a digital strategy that connects patients, providers, and payers. These comprehensive digital technology platforms are also effective tools for delivering competitive differentiation, better speed to market, and a source for new and expanded revenues.
Glaukos investor presentation updated as of 11282016 for website posstingglaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes minimally-invasive micro-scale injectable therapies to restore and enhance the eye's natural drainage system including the iStent, iStent Inject, and iStent Supra. Clinical trials demonstrate that a single iStent used in combination with cataract surgery achieves significant and sustained reductions in eye pressure and medication use through three years.
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their blood sugar levels as compared to a HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. SugarBEAT® can additionally be used as an adjunctive Continuous Glucose Monitoring (CGM) device by insulin users when calibrated by a finger stick reading.
Visit NMRDinfo.com for more information.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
Valeant provides revised guidance for Q4 2015 and full year 2015 due to impacts from separating from Philidor and transitioning to a new partnership with Walgreens, estimating a $250M revenue impact from Philidor separation and $150M from the Walgreens transition. Valeant also provides initial guidance for 2016, estimating $12.5-12.7B in revenue and $13.25-13.75 per share in adjusted EPS, representing over 20% growth compared to updated 2015 guidance.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Glaukos investor presentation for q2 2017 for website and 8_kglaukos
This document discusses Glaukos Corporation and its glaucoma treatment technologies. It contains the following key points:
- Glaukos is transforming glaucoma therapy with micro-scale injectable treatments that restore eye's natural drainage and reduce intraocular pressure, the only proven treatment for glaucoma.
- Their flagship product, iStent, is a single-use micro-bypass stent that has demonstrated long-term IOP reduction and medication reduction when used with cataract surgery based on multiple clinical studies.
- New products in development include iStent Inject for combination cataract/glaucoma procedures, iStent Supra to access a secondary drainage pathway, and iDose for targeted
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 25th Annual Credit Suisse Healthcare Conference on November 8, 2016. In the presentation, Barrett discussed how healthcare is rapidly transforming, with demands driven by demographics, science/technology, and a greater focus on outcomes. Cardinal Health is positioned to help customers navigate these complex changes through scaled solutions that optimize the healthcare process and connect clinicians and patients.
St. Jude Medical 2015 Annual Investor Meeting Presentationir_stjude
This document outlines St. Jude Medical's growth program for 2015. It discusses catalysts for growth including the full year impact of the CardioMEMS HF monitoring system and new ablation catheters. It also covers returning the neuromodulation business in the US to growth through new product launches. The presentation reviews delivering on financial commitments in 2014 and the outlook for continued sales and earnings growth in 2015 while maintaining strong cash flow and shareholder returns.
This document outlines St. Jude Medical's growth program for 2015. It discusses catalysts for growth including the full year impact of the CardioMEMS HF monitoring system and new ablation catheters. It also covers returning the neuromodulation business in the US to growth through new product launches. The presentation provides an overview of St. Jude Medical's markets, goals for financial metrics like sales and EPS growth, and focus on returning shareholder value through cash flow, dividends, and share repurchases.
This document provides a summary of key information from a Glaukos Corporation presentation:
- Glaukos is transforming glaucoma therapy through micro-scale injectable therapies like iStent that restore and enhance the eye's natural drainage system.
- Clinical trials show iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years while reducing medication needs by over 80%.
- US retrospective studies of over 100 eyes found iStent with cataract surgery lowered pressure 22% and medications 56% at 2 years.
- An international study demonstrated iStent's pressure lowering ability increases with 1, 2, or 3 stents implanted as a standalone procedure.
Cardinal Health plans to acquire Medtronic's Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion. The acquisition will expand Cardinal Health's product portfolio and presence across care settings. It is expected to be accretive to earnings per share beginning in fiscal year 2018 and generate over $150 million in annual synergies by fiscal year 2020. The acquisition will be funded with new debt and is expected to increase Cardinal Health's adjusted debt to EBITDA ratio to slightly over 2.0 times by the end of fiscal year 2020.
Merck & Co., Inc. at UBS Global Healthcare ConferenceDeepa K
Merck provided an overview of its business and outlook for 2015. Key points include:
1) Merck reported Q1 2015 global sales of $9.4 billion, with pharmaceutical sales up 5% and animal health up 13%.
2) Merck is focused on four key growth platforms: diabetes, vaccines, hospital acute care, and oncology.
3) Merck has several new product launches underway or planned for 2015 in these core areas, including KEYTRUDA, BELSOMRA, GARDASIL9, and ZERBAXA.
4) Merck's pipeline includes late-stage programs in areas with large unmet needs like hepatitis C, atherosclerosis,
Cardinal Health plans to acquire Medtronic's Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion. The acquisition will expand Cardinal Health's product portfolio and leadership in numerous medical product categories. It is expected to be accretive to Cardinal Health's earnings per share beginning in fiscal year 2018 and increasingly thereafter. Cardinal Health anticipates realizing over $150 million in annual synergies from the acquisition by the end of fiscal year 2020.
Art 1236 rev a-valeritas investor deck 2.0 final_031218bvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device that provides both basal and bolus insulin through a single-use, disposable patch. V-Go aims to help the millions of type 2 diabetes patients in the US who take insulin but struggle with adherence to multiple daily injections. Valeritas believes V-Go can become the preferred insulin delivery method for these patients by eliminating the need for injections. They are currently growing revenue quarter-over-quarter and targeting a $1.6 billion market opportunity by achieving a 15% share of the type 2 diabetes patients in the US who are not reaching their
Art 1236 rev c-valeritas investor deck 2.0_final_080618 web versionvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device for patients with type 2 diabetes. The presentation discusses Valeritas' significant market opportunity in the global diabetes pandemic, validates their new high-touch sales model which is driving accelerating revenue growth, and presents their attractive financial profile and path to profitability. Key risks to their projections include reliance on V-Go for revenue, ability to retain customers and achieve market acceptance, and manufacturing risks.
Nemaura Medical is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
What the Shift to Value Means for PharmaceuticalsMedullan
With the transition to value, payers are insisting that pharmaceutical manufacturers deliver real world evidence of their drug’s efficacy before being allowed on formulary. The cost of new specialty treatments has forced companies to bolster and go beyond clinical trial, proving that their drugs improve health outcomes and reduce the cost of care in actual use. Gathering and compiling the myriad of needed data points requires a digital strategy that connects patients, providers, and payers. These comprehensive digital technology platforms are also effective tools for delivering competitive differentiation, better speed to market, and a source for new and expanded revenues.
Glaukos investor presentation updated as of 11282016 for website posstingglaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes minimally-invasive micro-scale injectable therapies to restore and enhance the eye's natural drainage system including the iStent, iStent Inject, and iStent Supra. Clinical trials demonstrate that a single iStent used in combination with cataract surgery achieves significant and sustained reductions in eye pressure and medication use through three years.
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their blood sugar levels as compared to a HbA1c reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods up to 24 hours. SugarBEAT® can additionally be used as an adjunctive Continuous Glucose Monitoring (CGM) device by insulin users when calibrated by a finger stick reading.
Visit NMRDinfo.com for more information.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
Valeant provides revised guidance for Q4 2015 and full year 2015 due to impacts from separating from Philidor and transitioning to a new partnership with Walgreens, estimating a $250M revenue impact from Philidor separation and $150M from the Walgreens transition. Valeant also provides initial guidance for 2016, estimating $12.5-12.7B in revenue and $13.25-13.75 per share in adjusted EPS, representing over 20% growth compared to updated 2015 guidance.
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices,
coupled with artificial intelligence capabilities for digital healthcare. The company’s first product,
which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive
continuous glucose monitoring device and BEAT®diabetes digital healthcare platform.
sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real-time glucose measurements and daily glucose trend data,
which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage,
reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service
providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized
data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin
dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn
during waking hours and consists of a daily disposable adhesive skin-patch connected to a
rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
Glaukos investor presentation for q2 2017 for website and 8_kglaukos
This document discusses Glaukos Corporation and its glaucoma treatment technologies. It contains the following key points:
- Glaukos is transforming glaucoma therapy with micro-scale injectable treatments that restore eye's natural drainage and reduce intraocular pressure, the only proven treatment for glaucoma.
- Their flagship product, iStent, is a single-use micro-bypass stent that has demonstrated long-term IOP reduction and medication reduction when used with cataract surgery based on multiple clinical studies.
- New products in development include iStent Inject for combination cataract/glaucoma procedures, iStent Supra to access a secondary drainage pathway, and iDose for targeted
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 25th Annual Credit Suisse Healthcare Conference on November 8, 2016. In the presentation, Barrett discussed how healthcare is rapidly transforming, with demands driven by demographics, science/technology, and a greater focus on outcomes. Cardinal Health is positioned to help customers navigate these complex changes through scaled solutions that optimize the healthcare process and connect clinicians and patients.
St. Jude Medical 2015 Annual Investor Meeting Presentationir_stjude
This document outlines St. Jude Medical's growth program for 2015. It discusses catalysts for growth including the full year impact of the CardioMEMS HF monitoring system and new ablation catheters. It also covers returning the neuromodulation business in the US to growth through new product launches. The presentation reviews delivering on financial commitments in 2014 and the outlook for continued sales and earnings growth in 2015 while maintaining strong cash flow and shareholder returns.
This document outlines St. Jude Medical's growth program for 2015. It discusses catalysts for growth including the full year impact of the CardioMEMS HF monitoring system and new ablation catheters. It also covers returning the neuromodulation business in the US to growth through new product launches. The presentation provides an overview of St. Jude Medical's markets, goals for financial metrics like sales and EPS growth, and focus on returning shareholder value through cash flow, dividends, and share repurchases.
This document provides a summary of key information from a Glaukos Corporation presentation:
- Glaukos is transforming glaucoma therapy through micro-scale injectable therapies like iStent that restore and enhance the eye's natural drainage system.
- Clinical trials show iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years while reducing medication needs by over 80%.
- US retrospective studies of over 100 eyes found iStent with cataract surgery lowered pressure 22% and medications 56% at 2 years.
- An international study demonstrated iStent's pressure lowering ability increases with 1, 2, or 3 stents implanted as a standalone procedure.
Cardinal Health plans to acquire Medtronic's Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion. The acquisition will expand Cardinal Health's product portfolio and presence across care settings. It is expected to be accretive to earnings per share beginning in fiscal year 2018 and generate over $150 million in annual synergies by fiscal year 2020. The acquisition will be funded with new debt and is expected to increase Cardinal Health's adjusted debt to EBITDA ratio to slightly over 2.0 times by the end of fiscal year 2020.
Merck & Co., Inc. at UBS Global Healthcare ConferenceDeepa K
Merck provided an overview of its business and outlook for 2015. Key points include:
1) Merck reported Q1 2015 global sales of $9.4 billion, with pharmaceutical sales up 5% and animal health up 13%.
2) Merck is focused on four key growth platforms: diabetes, vaccines, hospital acute care, and oncology.
3) Merck has several new product launches underway or planned for 2015 in these core areas, including KEYTRUDA, BELSOMRA, GARDASIL9, and ZERBAXA.
4) Merck's pipeline includes late-stage programs in areas with large unmet needs like hepatitis C, atherosclerosis,
Cardinal Health plans to acquire Medtronic's Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion. The acquisition will expand Cardinal Health's product portfolio and leadership in numerous medical product categories. It is expected to be accretive to Cardinal Health's earnings per share beginning in fiscal year 2018 and increasingly thereafter. Cardinal Health anticipates realizing over $150 million in annual synergies from the acquisition by the end of fiscal year 2020.
Similar to Valeritas Investor Presentation August 2016 (20)
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
Cove Multifamily Income Fund 28 LLC IOI 3.3.2021 (1).pdf
Valeritas Investor Presentation August 2016
1. CONFIDENTIAL – AUTHORIZED USE ONLY
D E L I V E R I N G Q U A L I T Y O F L I F E
Investor Presentation
OTCQB: VLRX
John Timberlake, President & CEO
August 16, 2016
ART-923 Rev: B
Actual V-Go® Patient
2. 2
Forward Looking Statements
Thispresentationshallnotbe deemedan offerto sellsecuritiesnor a solicitationofan offerto purchasesecurities. Anysale bythe
companyshallbe madepursuantto a definitivepurchaseagreement.Unlessotherwisestatedin this presentation,referencesto
“Valeritas,”“we,”“us,”“our”or “ourcompany”referto ValeritasHoldings,Inc.and its subsidiaries.
Thispresentationcontainsestimates,projectionsand forward-lookingstatements.Our estimates,projectionsandforward-looking
statementsare basedon our management’scurrentassumptionsand expectationsof futureeventsandtrends,whichaffector may
affectour business,strategy,operationsor financialperformance.Althoughwe believethat theseestimates,projectionsand forward-
lookingstatementsare baseduponreasonableassumptionsand expectations,theyare subjectto numerousknownand unknownrisks
and uncertaintiesandare madein lightof informationcurrentlyavailableto us.Manyimportantfactorsmay adverselyand materially
affectour resultsas indicatedin forward-lookingstatements.All statementsotherthan statementsof historicalfact are forward-looking
statements.Thewords“believe,”“may,”“might,”“could,“would”,” “will,”“aim,”“estimate,”“continue,”“anticipate,”“intend,”
“expect,”“plan”and similarwordsare intendedto identifyestimates,projectionsandforward-lookingstatements.Estimates,
projectionsand forward-lookingstatementsspeakonlyas of the date theyare made,and,exceptto the extentrequiredbylaw,we
undertakeno obligationto updateor reviewany estimate,projectionor forward-lookingstatementbecauseof newinformation,future
eventsor otherfactors.
Our estimates,projectionsandforward-lookingstatementsmay be influencedbyoneor more of the followingfactors:
▫ ourhistoryof operatinglossesand uncertaintyregardingour abilityto achieveprofitability;
▫ ourrelianceon V-Go®DisposableInsulinDeliveryDevice,or V-Go,to generateall of our revenue;
▫ ourinabilityto retaina high percentageof our patientcustomerbaseor our significantwholesalecustomers;
▫ the failureof V-Goto achieveandmaintainmarketacceptance;
▫ ourinabilityto operatein a highlycompetitiveindustryandto competesuccessfullyagainstcompetitorswithgreaterresources;
▫ competitiveproductsand othertechnologicalbreakthroughsthat may renderV-Goobsoleteor lessdesirable;
▫ ourinabilityto maintainor expandoursalesand marketinginfrastructure;
▫ anyinaccuraciesin ourassumptionsaboutthe insulin-dependentdiabetesmarket;
▫ manufacturingrisks,includingrisksrelatedto manufacturingin SouthernChina,damageto facilitiesor equipmentand failureto
efficientlyincreaseproductionto meetdemand;
▫ ourdependenceon limitedsourcesuppliersand our inabilityto obtaincomponentsfor ourproduct;
▫ ourfailureto secureor retain adequatecoverageor reimbursementfor V-Goby third-partypayers;
▫ ourinabilityto enhanceand broadenour productoffering,includingthroughthe successfulcommercializationof the pre-fillV-Go;
▫ ourinabilityto protectourintellectualpropertyand proprietarytechnology;
▫ our failureto complywith theapplicablegovernmentalregulationsto whichour productand operationsare subject;
▫ ourabilityto operateas a goingconcern;and
▫ ourliquidity.
3. 3
Valeritas with V-Go® Disposable Insulin Delivery device
Compelling Investment in Type 2 Diabetes Market
Multi-Layered
Growth Strategy
Key Risks
Removed
Robust
Clinical Data
Large Market
Opportunity
~6M patients with
Type 2 on insulin
• ~4.5M not at A1C
goal of <7%
V-Go Disposable
Insulin Delivery
device addresses this
unmet need
$15B U.S. annual
market potential
Experienced
management team
Cleared in U.S. & EU
Established
reimbursement
Cost-neutral to
patients and payors
versus insulin pens
Commercial-scale
manufacturing with
>12M units
produced
Delivers clinically
relevant reductions
in A1C
Reduces total insulin
dose
More cost-effective
than MDI
Improved
convenience and
Quality of Life (QoL)
New capital efficient
model
Focused on increasing
sales rep productivity
Improving financial
metrics
• $18M 2015 Revenue
• Positive gross
margins
Scalable business
model with significant
growth opportunities
A1C refers to a blood test that correlates with a person’s average blood glucose level over a span of three months.
4. 4
V-Go® Disposable Insulin Delivery device:
The Ideal Device For Patients with Type 2 Diabetes
▫ Only FDA-cleared single-use, fully disposable insulin delivery
device with basal (background) and bolus (meal time)
capability on the market in the US
▫ Specifically designed to address unmet needs in Type 2
diabetes market
▫ Small, discreet, disposable and easy-to-use
▫ Convenient drug-like distribution model
▫ Reimbursed at the pharmacy –
where Type 2 patients go
5. 5
Key Differentiator: Focus on Large Type 2 Diabetes Market
The 4.6 Million Patients Valeritas Targets Represent a $15 Billion Market
Figures approximate. 2012 US Roper Diabetes Patient Market Study provided by GfK Customer Research LLC
Grabner M, Chen Y, Nguyen M, Abbott SD, Quimbo R. Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device. Clinicoecon Outcomes
Res. 2013 Sep 23;5:471-9.
Type 1
Type 2
TOTA L DIAGNO S E D W ITH DIA BE TES :
~22 million
5-10%
90-95%
~5.8 million on insulin
80%
not at A1C goal
(4.6 million)
A1C refers to a blood test that correlates with a person’s
average blood glucose level over a span of three months.
$15 Billion Annual
Opportunity(1)
(1) Based on V-Go® Wholesale Acquisition Price (WAC) of $283.93 per month x 12
months x 4.6 M Type 2 Patients on Insulin not at Goal. WAC price is the gross price sold
to wholesalers. The Company’s net price is WAC less fees, discounts and rebates.
(~3M >8% A1C)
6. 6
Patients with Type 2 Diabetes Require Basal and
Bolus Insulin Delivery to Maintain Glycemic Control
(1) Adapted from: Riddle. Diabetes Care. 1990;13:676-686
(2) Holman RR et al. N Engl J Med. 2009;361(18):1736-1747
82% of Patients with Type 2 Diabetes Initiated on Basal-Only Insulin Regimens Required
Mealtime Insulin to Achieve and Maintain A1C Goal(2)
PlasmaGlucose(mg/dL)(1)
200
100
0
6AM 12PM 6PM 12AM
Type 2 Diabetes
6AM
150
250
50
Mealtime /Prandial
Hyperglycemia
Normal Basal
Glucose Levels
ElevatedBasal
Glucose Levels
Time of Day
7. 7
Addresses Key Unmet Needs for Type 2 Patients on Insulin
V-Go® provides both background & mealtime insulin in a simple-to-use device
Complex
Physiologic
Nonphysiologic
Programmable Pump
Basal
Simple
Basal +1
or
Premix
>95% of Type 2 Patients
on Insulin
Intensive Therapy
8. 8
Complexity and Lack of Discretion can Result in Non-Compliance
72% Patients Prescribed ≥ 3 Shots/Day Reported They Do Not Inject Insulin Away From Home
Simplicity Ease-of-use Discretion
V-Go® SOLVES UNMET PATIENT NEEDS:
Data from U.S. Roper Diabetes Patient Market study provided by GfK Custom Research LLC and distributed only with express written permission of GfK
Custom Research LLC. This study is an annual survey of over 2,000 diabetes patients (n=2,104 in 2011; 692 who use insulin) via telephone and internet.
9. 9
V-Go® : Combines Simplicity and Physiologic Insulin
Preset basal rates of
insulin delivered at a
constant rate
On-demand insulin for mealtime
coverage in 2 units/click
Bolus
DeliveryButton
Activate Bolus Ready Button Deliver Insulin Repeat as Necessary
BolusReadyButton
Bolus
DeliveryButton
Bolus
Step
1
Bolus
Step
2
Bolus
Step
3
Confidential – Not For Distribution without Permission from Valeritas
Robust IP with 45 patents issued and 53 pending
10. 10
Simplifying Basal/Bolus Insulin Delivery for Patients with
Type 2 Diabetes
Discreet
No audible alerts
Mealtime dosing by clicking through their clothes
No need to carry supplies / No needles or pens
Easy to Use
Simple training process
No programing, batteries, or recharging
Daily disposable / daily routine
Convenient Access
Available at pharmacies across U.S.
As easy as prescription medication
Cost-Effective Cost neutral to insulin pens
What Patients with Type 2 Want …
11. 11
V-Go® vs. Traditional Type 1 Pumps & Controllers
V-Go has Numerous Advantages for the Type 2 Patient
Simplicity, Cost, Convenience, and QoL Favor V-Go for Type 2 Diabetes
Type 1 Pump & Controller
Reimbursement /
Distribution Pharmacy Benefit Medical Benefit via DME
Technology Mechanical / Simple Electronic / Complex /
Programmable
Pricing
Daily Disposable /
Pay-as-You-Go monthly
Durable (2 – 4 year reimbursement
cycle) plus Monthly Disposables
Training Burden Low (similar to insulin pens) High / Programmability
Competition
Insulin Pens
Syringes
Electronic Pump Companies
V-Go for Type 2
• Medtronic & Minimed
• J&J Animas
• Roche
• Insulet
• Tandem
12. 12
John Timberlake
President & Chief Executive Officer
26 / 10
Geoffrey Jenkins
EVP Manufacturing,Operations,R&D 30 / 7
Matt Nguyen
SVP Commercial
21 / 10
Erick Lucera
Chief FinancialOfficer
21 / -
The Valeritas Leadership Team
Proven Track Record of Success in Diabetes and Device Manufacturing
Years of Experience
Industry / Valeritas
13. 13
Commercial Execution Stage Company
Regulatory • 510(k) – U.S.
• CE Mark Certification – EU
Clinical Evidence • Strong efficacy data
• Cost-effectiveness data
Reimbursement
• ~70% commercial access
• ~60% Medicare D access
• TRICARE
Prescriber & Patient
Acceptance • Strong TRx uptake per sales rep
Manufacturing
• >12M Units produced to date
• Replicated multiple lines at CMO
• Positive gross margins
14. 14
V-Go® is Accessible and More Convenient Through Pharmacies
Type 2 Patients Generally Fill Their Insulin and Other Medications at the Pharmacy
• Enhanced Patient Convenience
• Traditional Co-pay at Pharmacy
~90% Distribution
Through Wholesalers
Sold at Pharmacy / Retail Outlets
V-Go for Type 2 Diabetes
V-Go
Durable Medical
Equipment
Type 1 Durable Pump
Type 1 Pump Maker
• Requires Medical Necessity
• Annual Medical Deductibles
• Monthly Medical Co-
insurance
15. 15
Established Reimbursement with Pharmacy Benefit
164 M Pharmacy Lives*
Diabetes Prevalence >20 Yrs. old: 12.3%
34 M TotalLives*
Diabetes Prevalence >65 Yrs. old: 18.9%
• Over 90% of V-Go Prescriptions Filled at Retail Pharmacies since Launch
• TRICARE & State Medicaid Cover V-Go Under Pharmacy and/or Medical Benefit
All Access figures as of December 2014. Prevalence data : ADA 2013 Fact Sheet and the CDC Diabetes Report Card 2012.
* Commercial Pharmacy Lives: Health Leaders InterStudy 2013: Decision Resources, Medicare Part D Lives: Pathfinder Rx Database 2/1/15.
60%+ Medicare Part D Access70%+ Commercial Access
< 30%
of Lives
Not Covered
or Restricted
Access
70%+
of Lives
V-Go Covered
Under
Insurance
< 40%
of Lives
Not on
Formulary–
Accessthrough
Medical
Exception
60%+
of Lives
V-Go Covered
Under
Pharmacy
Insurance
16. 16
Pharmacy Benefit Reimbursement Model
Cost-effective for both Payors & Patients
V-Go® Therapy
Basal/Bolus Pen Therapy
Neutral Cost to Payors
(~$20/day) between Regimens*
*What a Payor Pays (Net of Rebates & Co-pays
when V-Go Contracted in Preferred Position)
$31
co-pay
$31
co-pay
$11
co-pay
$31
co-pay
$31 or $53
co-pay1
$73
co-pay
$62 or $84
co-pay(1)
(1) Avg. Nat’l Tier 2 or Tier 3 Co-pay for commercial plans is $31 and $53, respectively, The Kaiser Family
Foundation and Health Research & Education Trust Employer Health Benefits 2014 Annual Survey.
Neutral Cost to Patients (+/- $11)
17. 17
Extensive Patient Experience With Proven Quality
V-Go® product quality demonstrated with >8M devices used successfully
Source: Symphony Health Solutions (Retail and Mail Order).
V-Go adherence & persistency better than most Type 2 regimens (injections or pills)
5 Million
3 Million
1 Million
8 Million
18. 18
(1) Rosenfeld CR, et al. Endocr Pract. 2012; 18 (5):660-667; (2) Grunberger, G, et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 985-P; (3) Omer, A. et
al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 980-P; (4) Lajara, et al. Drugs-Real World Outcomes [First online 02 June 2016]; (5) Lajara R, et al.
Diabetes Ther. 2015;6 (4):531-545 ; (6) Lajara R et al. Endocr Pract. 2016 June; 22 (6): 726-725.
Strong and Extensive Data Supports Broad Adoption
Statistically Significant
Improvements in A1C(1-6)1
Improved Quality of Life(1)
2
Lowered Total Daily Insulin Dose
(Prescribed / Administered)(1-6)3
Demonstrated Cost Reductions(4)
4
9
Published
Clinical
Papers
34
Posters at
Medical
Meetings
~700
patients studied
19. 19
Better Glycemic Control Improves and Extends Lives
Significant Adverse Health Effects Influenced by Poor Glycemic Control
Stratton IM et al. BMJ. 2000;321:405-412.
21%
Deaths from Diabetes
14%
Heart Attacks
37%
Microvascular
Complications
43%
Peripheral Vascular
Disease
Each 1% reduction in mean A1C
reduces risk for
20. 20
Robust Clinical Data Validates V-Go®’s Ability to Deliver
Clinically Relevant Reductions in A1C Levels
-1.0
-2.0
-2.4
-1.2
-1.9
-1.2
-2.3
-3.4
-1.8
-1.5
ChangeinA1C
BL= Baseline
(1) Grunberger G, et al. Poster presented at: American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress. May 14-18, 2014; Las Vegas, NV.
(2) Lajara R, Davidson JA, et al. Endocr Pract. 2016 June; 22 (6): 726-725.
(3) Omer, A. et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 980-P.
(4) Rosenfeld CR, et al. Endocr Pract. 2012; 18 (5):660-667.
(5) Sandberg, M, Martinez, J. Practical Diabetology. 2013;32(3): 6–22.
(6) Lajara, et al. Poster presented at 2015 AACE Annual Scientific & Clinical Congress, May 13-17, 2015, Nashville, TN.
(7) Lajara R, et al. Diabetes Ther. 2015;6 (4):531-545
N’s=SIMPLE-59,EndocrinePractice-56,UMASS-14,UPP-23,EAP-16,DAMDI-56,DABasal-32 DA,DAInsulinNaïve-24,DAT2-175 DAT1/LADA-29.AllpatientsforDA-204.
Clinically Relevant (-0.5%)
SIMPLE(1)
Basal Cohort
BL: 8.7%
9 Months
DA(2)
Vs. MDI
BL: 9.5%
~7 Months
UMASS(3)
All Cohorts
BL: 10.7%
3 Months
UPP(4)
All Cohorts
BL: 8.8%
3 Months
EAP(5)
All Cohorts
BL: 9.3%
3 Months
DA(6)
MDI Cohort
BL: 9.4%
~6 Months
DA(6)
Basal Cohort
BL: 9.6%
~6 Months
DA(7)
Insulin Naive
BL: 11.3%
~7 Months
DA(7)
T1/LADA Cohort
BL: 9.5%
~7 Months
DA(7)
T2 Cohort
BL: 9.7%
~7 Months
21. 21
Switching to V-Go® Demonstrated Significant Reductions in
Total Daily Insulin Dose (TDD) Across Multiple Studies
-18%
-46%
-13%
-22%
-20%
-41%
-28%
%ChangeinInsulin
(1) Grunberger, G, et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 985-P (all patients – 3 months).
(2) Omer, A. et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 980-P (percent reduction based on units/kg).
(3) Data on file.
(4) Data on file.
(5) Sink JH et al. Poster presented at Diabetes Technology Meeting. November 6-8, 2014; Bethesda, MD.
(6) Lajara R, et al. Diabetes Ther. 2015;6 (4):531-545
(7) Lajara R, Davidson JA, et al. Endocr Pract. 2016 June; 22 (6): 726-725. Difference in mean Insulin TDD at end of study MDI 78 U/day vs V-Go 56 U/day.
*Change in basal component of TDD only value available
Diabetes
America(6)
99 U TDDBaseline
UPP(3)
56 U TDD
EAP(4)
Basal Dose*
UMASS(2)
119 U TDD
SIMPLE(1)
62 U TDD
Jones
Center(5)
76 U TDD
Diabetes
America(7)
78 U TDD
22. 22
6.0
7.0
8.0
9.0
10.0
11.0
Pre V-Go On V-Go
10.7
8.3*
A1C(%)
N=14 Average Duration = 88 days
0
20
40
60
80
100
120
140
Pre V-Go On V-Go
119
64†
InsulinTDD(units)
† P=0.01, *P=0.001
Change
-2.4
Change
-55 U
V-Go® Significantly Reduces A1C with Less Insulin
Key Benefit to Both Patients and Payors
(1) Based on Insulin TDD absolute units.
Omer, A. et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 980-P.
UMASS Study .
Change
-2.4
- 55U
Change
= 46%(1)
- 2.4
23. 23
7.7*
7.6*
8.4*
8.1*
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
Baseline 12 week 27 week
A1C(%)
V-Go: N=56 BL A1C- 9.5% BL TDD - 51 U/day, Starting V-Go TDD- 52 U/day, 12 week TDD- 56 U/day, 27 week TDD- 56 U/day
MDI: N=60 BL A1C- 9.4%, BL TDD- 46 U/day, Starting MDI TDD- 64 U/day, 12 week TDD- 75 U/day, 27 week TDD- 78 U/day
Data are mean (SE)
P=0.02
V-Go® Demonstrates Significant Improvements In
Glycemic Control vs Multiple Daily Injections (MDI)
Lajara R, Davidson JA, et al. Endocr Pract. 2016 June; 22 (6): 726-725.
Better Control with Less Insulin vs MDI
MDI
V-Go
30
40
50
60
70
80
90
51 units 46 units
56
78*
TDD(U/day)at27weeks
Baseline
P<0.0001
MDIV-Go
24. 24
$0
$50
$100
$150
$200
$250
$217.16
$118.84
Insulin costs include both the insulin and associated delivery method. The costs of insulin were normalized by calculating a 30 day insulin requirement based on the total
prescribed daily insulin dose for each insulin and multiplying the monthly dose in units by the unit cost. Only branded antihyperglycemic agents were included in total
therapy costs. All pricing based on published wholesale acquisition costs in 2015 U.S. dollars as of 9/1/2015.
†P-value calculated using the cost inferential per 1% reduction using least squares mean A1C reductions at 27 weeks.
V-Go® is a More Cost-Effective Therapy vs. MDI
Lajara R, Davidson JA, et al. Endocr Pract. 2016 June; 22 (6): 726-725.
V-Go Reduced Direct Pharmacy Costs by 45% per 1% Reduction in A1C
† P=0.013
MDI V-Go
DirectPharmacyCostPerMonth
Per1%reductioninA1C
25. 25
28% 27%
10%
53%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
SurveyRespondents
Convenience(1)
Very
Convenient
Somewhat
Convenient
Note: Patients were surveyed prior to starting V-Go and again ~30 days after being on V-Go.
Patients Rate the Convenience of V-Go® and Their
Quality of Life as Superior vs. Previous Therapies
Prior
Therapy
V-Go
Therapy
(1) Data on File (Valeritas Customer Care).
29%
44%
6%
20%
0%
10%
20%
30%
40%
50%
60%
70%
Prior
Therapy
V-Go
TherapySurveyRespondents
Quality of Life(2)
Excellent
Generally
Good
How do you feel physically &
mentally on a typical day?
27. 27
Strengthened, Focused, Capital-Efficient Business
Broad U.S. focus
& capital-intensive
~64
Low productivity due to rapid
territory expansion & wide
geographic dispersion
~12M Units
$(15.7)M
1Q16
COMMERCIAL
STRATEGY
SALES TERRITORIES
REP PRODUCTIVITY
MANUFACTURING
CAPACITY
High-volume U.S. territories
& capital-efficient
~27
Driving to optimal
productivity
~16M Units
$(9.6)M
1Q15
OPERATING
LOSS
28. 28
Newly Focused and Capital Efficient Commercial Strategy
Target high
prescribing
physicians
Increase
frequency
of office
contact
Educate
HCP’s on
pharmacy
model and
access
Ensure
optimal
patient
selection
Focused
marketing
and patient
support
HCP – Healthcare Professionals, which include Prescribers, Physician office staff and retail pharmacies.
29. 29
Revised Commercial Model Focused on Driving
Sales Rep Productivity
Cust. Care
Promo
Services
3rd Party
Peer to Peer
sales
DTP
TRx/Month/Rep
Inside
Sales
Top performing territories
Low performing
territories
Vacated
territories
• Greater & strengthened support resources focused on prioritized higher-volume territories
• Less capital-intensive model
• Focus on fewer high-volume
prescribers
• Utilize fewer field-based sales
reps
• Increase prescriber contacts
through
• Weekly calls by sales reps
• Inside sales team calls
• Third party clinical team calls
• Focused promotional spend
• Targeted direct to patient
efforts in territories with field-
based sales reps
• Minimize prescription
erosion in vacated territories
30. 30
$0.6
$6.2
$13.5
$18.1
2012 2013 2014 2015 2016 est.
Valeritas: Financial Profile
Poised for Growth and Profitability Ahead of Industry Peers
Revenue ($ in millions)
Annual Revenue (March 2012 – December 2015)
34%
118%
~ 64sales
reps
~ 27sales
reps*
~ 64sales
reps
~ 64sales
reps
2016
Greater Sales
Productivity
on a per
Territory
Basis
With a
Significant
Reduction in
Cash Burn
$9.9
1H’16
2Q16 Financial Summary ($ in millions) 2Q16 2Q15 Change
Revenue $4.9 $4.6 6%
Gross Margin 35.5% 13.9% +214bps
Operating Expenses $9.7 $13.3 (27)%
Net Loss $10.5 $16.2 (35)%
Cash $20.4 $2.8 628%
* The Company completed a restructuring in February 2016 and estimates it will have an average of 27 filled sales territories over the ten months
between March and December 2016.
31. 31
Commercial-Execution Stage Company with
Substantial Growth Opportunities
Regulatory • 510(k) – U.S.
• CE Mark Certification – EU
Clinical Evidence • Strong efficacy data
• Cost-effectiveness data
Reimbursement
• >70% commercial access
• >60% Medicare D access
• TRICARE
Prescriber & Patient
Acceptance
• Strong TRx uptake per
sales rep
Manufacturing • >12M Units produced to date
• >10M Units from our CMO
Advancing Type 2 Basal /
Bolus Insulin Delivery
Growth Opportunities / Catalysts
▫ U.S.
– Execute our capital-efficient model
– Early 2017 expansion of sales force based
on new focused model
– Continued reimbursement opportunities
▫ International Market Licensing or
Distribution
▫ Next Generation V-Go® Pre-fill
▫ Platform Expansion
– Other therapeutics (e.g. Pain Therapy)
32. CONFIDENTIAL – AUTHORIZED USE ONLY
D E L I V E R I N G Q U A L I T Y O F L I F E
Thank you
Actual V-Go® Patient
ART-923 Rev: B